No Data
No Data
No Data
No Data
No Data
Express News | HC Wainwright & Co. Reiterates Buy on Indaptus Therapeutics, Maintains $12 Price Target
Moomoo 24/7Apr 15 06:08 ET
Indaptus Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/15/2024 322.54% HC Wainwright & Co. → $12 Reiterates Buy → Buy 09/20/2023 322.54% HC Wainwright & Co. →
BenzingaApr 15 06:06 ET
Buy Rating for Indaptus Therapeutics: Promising Oncology Breakthrough With Decoy20 Platform
TipRanksApr 12 15:05 ET
Express News | Indaptus Therapeutics Unveils Details On Mechanism Of Action Data That Demonstrates The Company's Decoy Platform Induces, Matures Or Activates Multiple Immune Cell Types Involved In Anti-tumor Responses, At AACR Research Annual Meeting
Moomoo 24/7Apr 11 07:35 ET
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersProtara Therapeutics (NASDAQ:TARA) stock increased by 40.3% to $5.64 during Friday's pre-market session. The market value of their outstanding shares is at $64.4 million. Candel Therapeutics (N
BenzingaApr 5 08:09 ET
Indaptus Therapeutics Previews Mechanism Of Action Data To Be Presented At The American Association For Cancer Research Annual Meeting
Data demonstrates that Company's Decoy platform successfully induces or activates multiple immune celltypes involved in anti-tumor responsesNew data shows activity in M1 macrophages, natural killer ce
BenzingaMar 25 08:41 ET
No Data
No Data